BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. Full Press Release: https://bit.ly/PSTV_PR #braincancer #pediatriconcology #clinicaltrials
Recent Comments